Return to homepagePandemic Pact

IAVI

  • Funded by Coalition for Epidemic Preparedness Innovations (CEPI)
  • Total publications:0 publications

Grant number: CEPI-1785

Grant search

Key facts

  • Disease

    Disease X

  • Start & end year

    2026

  • Known Financial Commitments (USD)

    $3,200,000

  • Funder

    Coalition for Epidemic Preparedness Innovations (CEPI)

  • Research Location

    99

  • Lead Research Institution

    IAVI

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Vaccine trial design and infrastructure

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

CEPI has committed initial funding of up to US$3.2 million for preparations necessary to generate a Master Virus Seed stock – the starting material needed to manufacture a vaccine – and initiate testing of the seed in an established process using material originally developed at The University of Texas Medical Branch. This candidate uses the rVSV vaccine platform upon which an approved and WHO-prequalified vaccine against Zaire ebolavirus is based. Rapid onset of protective immunity after one dose is a key feature of vaccines using this platform, which is critical when vaccines are deployed in an outbreak setting.